Skip to main content

Amikacin Side Effects

Medically reviewed by Last updated on Oct 21, 2023.

Applies to amikacin: injection solution.


Injection route (Solution)

Therapy has been associated with potential neurotoxicity, ototoxicity, and nephrotoxicity. Patients with impaired renal function, advanced age, dehydration, and those who receive high dosage or prolonged therapy are at an increased risk of toxicity. Monitor renal and auditory function during therapy and discontinue therapy or adjust dose if there is evidence of ototoxicity or nephrotoxicity. Aminoglycoside-induced ototoxicity is usually irreversible. Serum concentrations of aminoglycosides should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. Neuromuscular blockade and respiratory paralysis have also been reported following administration. Concurrent use of other potentially neurotoxic agents, nephrotoxic agents, or potent diuretics should be avoided.

Serious side effects of Amikacin

Along with its needed effects, amikacin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking amikacin:

Incidence not known

Other side effects of Amikacin

Some side effects of amikacin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to amikacin: compounding powder, injectable solution, intravenous solution.


The most commonly reported side effects included injection site paint and hearing loss (permanent in some cases).[Ref]


Renal function changes were usually reversible when the drug was discontinued.[Ref]

Common (1% to 10%): Azotemia, decreased creatinine clearance, decreased renal function, increased serum creatinine, increased serum urea

Uncommon (0.1% to 1%): Renal failure

Frequency not reported: Acute renal failure, cells in urine, renal toxicity, toxic nephropathy[Ref]


Initial hearing loss usually manifests as diminution of high-tone acuity.[Ref]

Common (1% to 10%): Hearing loss, permanent hearing loss

Uncommon (0.1% to 1%): Changes in caloric testing/electronystagmus, drug fever

Rare (0.01% to 0.1%): Pyrexia

Frequency not reported: Auditory toxicity, cochlear damage, deafness, generalized burning, high frequency deafness, lethargy, neurosensory deafness, ototoxicity, vestibular toxicity[Ref]


Common (1% to 10%): Oliguria, protein in the urine

Rare (0.01% to 0.1%): Albuminuria, red blood cells in urine, white blood cells in urine[Ref]


Injection site pain occurred with IM administration.[Ref]

Common (1% to 10%): Injection site pain[Ref]

Nervous system

Uncommon (0.1% to 1%): Dizziness, paresthesia, tremor, vertigo

Rare (0.01% to 0.1%): Balance disorder, headache

Frequency not reported: Acute organic brain syndrome, confusion, convulsions, eighth cranial nerve toxicity, loss of balance, neuromuscular blockade, paralysis, pseudotumor cerebri[Ref]


Uncommon (0.1% to 1%): Nausea, vomiting

Frequency not reported: Increased salivation, stomatitis[Ref]


Uncommon (0.1% to 1%): Superinfections or colonization with resistant bacteria or yeast[Ref]


Uncommon (0.1% to 1%): Rash/skin rash

Rare (0.01% to 0.1%): Pruritus, urticaria

Frequency not reported: Alopecia[Ref]


Uncommon (0.1% to 1%): Arthralgia

Rare (0.01% to 0.1%): Muscle twitching

Frequency not reported: Acute muscular paralysis, joint pain, myasthenia gravis-like syndrome[Ref]


Uncommon (0.1% to 1%): Anemia

Rare (0.01% to 0.1%): Eosinophilia

Frequency not reported: Purpura, splenomegaly[Ref]


Uncommon (0.1% to 1%): AST increased

Frequency not reported: Transient hepatomegaly[Ref]


Rare (0.01% to 0.1%): Blindness, macular infarction, permanent vision loss, retinal infarction

Frequency not reported: Visual disturbances[Ref]

Blindness, macular infarction, and retinal infarction occurred after intravitreous administration.[Ref]


Rare (0.01% to 0.1%): Hypomagnesemia

Frequency not reported: Anorexia, decreased appetite, weight loss[Ref]


Rare (0.01% to 0.1%): Hypotension

Frequency not reported: Hypertension[Ref]


Frequency not reported: Anaphylactic reaction, anaphylactic response, anaphylactic shock, anaphylactoid reaction, hypersensitivity[Ref]


Frequency not reported: Apnea, bronchospasm, laryngeal edema, pulmonary fibrosis, respiratory depression[Ref]


Frequency not reported: Depression[Ref]

Frequently asked questions


1. (2002) "Product Information. Amikin (amikacin)." Bristol-Myers Squibb

2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

3. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.